The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie A Razavi; Imam A Waked; Christoph M Sarrazin; Robert P Myers; Ramazan Idilman; Filipe Calinas; W Vogel; Maria Cassia Jacintho Mendes-Correa; Christophe Hezode; P Lazaro; Ulus Salih Akarca; Soo Aleman; Ismail Balik; T Berg; Florian K Bihl; M Bilodeau; A J Blasco; Carlos Eduardo Brandao-Mello; Philip Bruggmann; Maria Asuncion Buti; J L Calleja; Hugo Cheinquer; P B Christensen; M Clausen; H S M Coelho; Matthew E Cramp; Gregory J Dore; Wahid H Doss; Ann Sofi Duberg; M H El-Sayed; Gul Ergor; Gamal Esmat; K Falconer; J Felix; M L G Ferraz; P R Ferreira; Sona Frankova; Javier Garcia-Samaniego; J Gerstoft; Jose A Giria; Fernando Lopes Goncales; Erin E Gower; Michael Gschwantler; M Guimaraes Pessoa; S J Hindman; H Hofer; P Husa; M Kaberg; Kelly Kaita; Achim Kautz; Sabahattin Kaymakoglu; Mel Krajden; H Krarup; Wim J Laleman; D Lavanchy; R T Marinho; P Marotta; Stefan Mauss; Christophe A Moreno; K Murphy; Francesco Negro; V Nemecek; Necati Ormeci; Anne Lindebo Holm Ovrehus; J Parkes; Ken Pasini; Kevork Minas Peltekian; Alnoor S Ramji; N Reis; Stuart Keith Roberts; William M C Rosenberg; Francoise Roudot-Thoraval; Stephen D Ryder; Rui Sarmento-Castro; David Semela; M Sherman; Gamal Elsayed Shiha; William Sievert; J Sperl; Peter Starkel; R E Stauber; Alexander James V Thompson; P Urbanek; P Van Damme; I Van Thiel; H Van Vlierberghe; Dominique M Vandijck; Heiner Wedemeyer; N Weis; J Wiegand; Ayman Yosry; Amany Zekry; Markus Cornberg; B Mullhaupt; Chris Estes

doi:10.1111/jvh.12248

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie A Razavi, Imam A Waked, Christoph M Sarrazin, Robert P Myers, Ramazan Idilman, Filipe Calinas, W Vogel, Maria Cassia Jacintho Mendes-Correa, Christophe Hezode, P Lazaro, Ulus Salih Akarca, Soo Aleman, Ismail Balik, T Berg, Florian K Bihl, M Bilodeau, A J Blasco, Carlos Eduardo Brandao-Mello, Philip Bruggmann, Maria Asuncion ButiJ L Calleja, Hugo Cheinquer, P B Christensen, M Clausen, H S M Coelho, Matthew E Cramp, Gregory J Dore, Wahid H Doss, Ann Sofi Duberg, M H El-Sayed, Gul Ergor, Gamal Esmat, K Falconer, J Felix, M L G Ferraz, P R Ferreira, Sona Frankova, Javier Garcia-Samaniego, J Gerstoft, Jose A Giria, Fernando Lopes Goncales, Erin E Gower, Michael Gschwantler, M Guimaraes Pessoa, S J Hindman, H Hofer, P Husa, M Kaberg, Kelly Kaita, Achim Kautz, Sabahattin Kaymakoglu, Mel Krajden, H Krarup, Wim J Laleman, D Lavanchy, R T Marinho, P Marotta, Stefan Mauss, Christophe A Moreno, K Murphy, Francesco Negro, V Nemecek, Necati Ormeci, Anne Lindebo Holm Ovrehus, J Parkes, Ken Pasini, Kevork Minas Peltekian, Alnoor S Ramji, N Reis, Stuart Keith Roberts, William M C Rosenberg, Francoise Roudot-Thoraval, Stephen D Ryder, Rui Sarmento-Castro, David Semela, M Sherman, Gamal Elsayed Shiha, William Sievert, J Sperl, Peter Starkel, R E Stauber, Alexander James V Thompson, P Urbanek, P Van Damme, I Van Thiel, H Van Vlierberghe, Dominique M Vandijck, Heiner Wedemeyer, N Weis, J Wiegand, Ayman Yosry, Amany Zekry, Markus Cornberg, B Mullhaupt, Chris Estes

Research output: Contribution to journal › Article › Research › peer-review

349 Citations (Scopus)

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today s treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

Original language	English
Pages (from-to)	34 - 59
Number of pages	26
Journal	Journal of Viral Hepatitis
Volume	21
Issue number	Supplement S1
DOIs	https://doi.org/10.1111/jvh.12248
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.12248

Cite this

Razavi, H. A., Waked, I. A., Sarrazin, C. M., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes-Correa, M. C. J., Hezode, C., Lazaro, P., Akarca, U. S., Aleman, S., Balik, I., Berg, T., Bihl, F. K., Bilodeau, M., Blasco, A. J., Brandao-Mello, C. E., Bruggmann, P., ... Estes, C. (2014). The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 21(Supplement S1), 34 - 59. https://doi.org/10.1111/jvh.12248

@article{b0bae993a3bb40618d3980f52617a484,

title = "The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm",

abstract = "The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today s treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.",

author = "Razavi, {Homie A} and Waked, {Imam A} and Sarrazin, {Christoph M} and Myers, {Robert P} and Ramazan Idilman and Filipe Calinas and W Vogel and Mendes-Correa, {Maria Cassia Jacintho} and Christophe Hezode and P Lazaro and Akarca, {Ulus Salih} and Soo Aleman and Ismail Balik and T Berg and Bihl, {Florian K} and M Bilodeau and Blasco, {A J} and Brandao-Mello, {Carlos Eduardo} and Philip Bruggmann and Buti, {Maria Asuncion} and Calleja, {J L} and Hugo Cheinquer and Christensen, {P B} and M Clausen and Coelho, {H S M} and Cramp, {Matthew E} and Dore, {Gregory J} and Doss, {Wahid H} and Duberg, {Ann Sofi} and El-Sayed, {M H} and Gul Ergor and Gamal Esmat and K Falconer and J Felix and Ferraz, {M L G} and Ferreira, {P R} and Sona Frankova and Javier Garcia-Samaniego and J Gerstoft and Giria, {Jose A} and Goncales, {Fernando Lopes} and Gower, {Erin E} and Michael Gschwantler and {Guimaraes Pessoa}, M and Hindman, {S J} and H Hofer and P Husa and M Kaberg and Kelly Kaita and Achim Kautz and Sabahattin Kaymakoglu and Mel Krajden and H Krarup and Laleman, {Wim J} and D Lavanchy and Marinho, {R T} and P Marotta and Stefan Mauss and Moreno, {Christophe A} and K Murphy and Francesco Negro and V Nemecek and Necati Ormeci and Ovrehus, {Anne Lindebo Holm} and J Parkes and Ken Pasini and Peltekian, {Kevork Minas} and Ramji, {Alnoor S} and N Reis and Roberts, {Stuart Keith} and Rosenberg, {William M C} and Francoise Roudot-Thoraval and Ryder, {Stephen D} and Rui Sarmento-Castro and David Semela and M Sherman and Shiha, {Gamal Elsayed} and William Sievert and J Sperl and Peter Starkel and Stauber, {R E} and Thompson, {Alexander James V} and P Urbanek and {Van Damme}, P and {Van Thiel}, I and {Van Vlierberghe}, H and Vandijck, {Dominique M} and Heiner Wedemeyer and N Weis and J Wiegand and Ayman Yosry and Amany Zekry and Markus Cornberg and B Mullhaupt and Chris Estes",

year = "2014",

doi = "10.1111/jvh.12248",

language = "English",

volume = "21",

pages = "34 -- 59",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "Supplement S1",

}

Razavi, HA, Waked, IA, Sarrazin, CM, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes-Correa, MCJ, Hezode, C, Lazaro, P, Akarca, US, Aleman, S, Balik, I, Berg, T, Bihl, FK, Bilodeau, M, Blasco, AJ, Brandao-Mello, CE, Bruggmann, P, Buti, MA, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, WH, Duberg, AS, El-Sayed, MH, Ergor, G, Esmat, G, Falconer, K, Felix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, Garcia-Samaniego, J, Gerstoft, J, Giria, JA, Goncales, FL, Gower, EE, Gschwantler, M, Guimaraes Pessoa, M, Hindman, SJ, Hofer, H, Husa, P, Kaberg, M, Kaita, K, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, WJ, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, CA, Murphy, K, Negro, F, Nemecek, V, Ormeci, N, Ovrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, AS, Reis, N, Roberts, SK, Rosenberg, WMC, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Starkel, P, Stauber, RE, Thompson, AJV, Urbanek, P, Van Damme, P, Van Thiel, I, Van Vlierberghe, H, Vandijck, DM, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Mullhaupt, B & Estes, C 2014, 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', Journal of Viral Hepatitis, vol. 21, no. Supplement S1, pp. 34 - 59. https://doi.org/10.1111/jvh.12248

TY - JOUR

T1 - The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

AU - Razavi, Homie A

AU - Waked, Imam A

AU - Sarrazin, Christoph M

AU - Myers, Robert P

AU - Idilman, Ramazan

AU - Calinas, Filipe

AU - Vogel, W

AU - Mendes-Correa, Maria Cassia Jacintho

AU - Hezode, Christophe

AU - Lazaro, P

AU - Akarca, Ulus Salih

AU - Aleman, Soo

AU - Balik, Ismail

AU - Berg, T

AU - Bihl, Florian K

AU - Bilodeau, M

AU - Blasco, A J

AU - Brandao-Mello, Carlos Eduardo

AU - Bruggmann, Philip

AU - Buti, Maria Asuncion

AU - Calleja, J L

AU - Cheinquer, Hugo

AU - Christensen, P B

AU - Clausen, M

AU - Coelho, H S M

AU - Cramp, Matthew E

AU - Dore, Gregory J

AU - Doss, Wahid H

AU - Duberg, Ann Sofi

AU - El-Sayed, M H

AU - Ergor, Gul

AU - Esmat, Gamal

AU - Falconer, K

AU - Felix, J

AU - Ferraz, M L G

AU - Ferreira, P R

AU - Frankova, Sona

AU - Garcia-Samaniego, Javier

AU - Gerstoft, J

AU - Giria, Jose A

AU - Goncales, Fernando Lopes

AU - Gower, Erin E

AU - Gschwantler, Michael

AU - Guimaraes Pessoa, M

AU - Hindman, S J

AU - Hofer, H

AU - Husa, P

AU - Kaberg, M

AU - Kaita, Kelly

AU - Kautz, Achim

AU - Kaymakoglu, Sabahattin

AU - Krajden, Mel

AU - Krarup, H

AU - Laleman, Wim J

AU - Lavanchy, D

AU - Marinho, R T

AU - Marotta, P

AU - Mauss, Stefan

AU - Moreno, Christophe A

AU - Murphy, K

AU - Negro, Francesco

AU - Nemecek, V

AU - Ormeci, Necati

AU - Ovrehus, Anne Lindebo Holm

AU - Parkes, J

AU - Pasini, Ken

AU - Peltekian, Kevork Minas

AU - Ramji, Alnoor S

AU - Reis, N

AU - Roberts, Stuart Keith

AU - Rosenberg, William M C

AU - Roudot-Thoraval, Francoise

AU - Ryder, Stephen D

AU - Sarmento-Castro, Rui

AU - Semela, David

AU - Sherman, M

AU - Shiha, Gamal Elsayed

AU - Sievert, William

AU - Sperl, J

AU - Starkel, Peter

AU - Stauber, R E

AU - Thompson, Alexander James V

AU - Urbanek, P

AU - Van Damme, P

AU - Van Thiel, I

AU - Van Vlierberghe, H

AU - Vandijck, Dominique M

AU - Wedemeyer, Heiner

AU - Weis, N

AU - Wiegand, J

AU - Yosry, Ayman

AU - Zekry, Amany

AU - Cornberg, Markus

AU - Mullhaupt, B

AU - Estes, Chris

PY - 2014

Y1 - 2014

N2 - The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today s treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

AB - The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today s treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

UR - http://onlinelibrary.wiley.com/doi/10.1111/jvh.12248/pdf

U2 - 10.1111/jvh.12248

DO - 10.1111/jvh.12248

M3 - Article

SN - 1352-0504

VL - 21

SP - 34

EP - 59

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - Supplement S1

ER -

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Abstract

UN SDGs

Access to Document

Other files and links

Cite this